Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 2/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278360 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL12636892 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL26813473 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL29766904 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL17423276 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL7303364 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL17423280 | 1.00 | OXTR (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL30515732 | 0.99 | MEN1 (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL29371071 | 0.99 | MEN1 (1.00) | OXTRAVPR2AVPR1ACYP3A4TSHR | |
| SCHEMBL7305556 | 0.93 | OXTR (0.87) | OXTRAVPR2AVPR1ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235556-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. | 2014-08-21 | — | — | US | claimed |
| EP-2760473-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | Biomed Valley Discoveries, Inc. (US) | 2014-08-06 | — | — | EP | claimed |
| CN-103930132-A | Compositions and methods of treating gliomas | BIOMED VALLEY DISCOVERIES INC | 2014-07-16 | — | — | CN | claimed |
| WO-2013049045-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-11752157-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (NL) | 2023-09-12 | — | — | US | disclosed |
| CN-113940990-A | Oxytocin receptor antagonists | 辉凌有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-107249618-B | Oxytocin receptor antagonist treatment in the luteal phase of implantation and pregnancy in women undergoing assisted reproductive technologies | 辉凌有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20200352962-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING B.V. (NL) | 2020-11-12 | — | — | US | disclosed |
| US-10688106-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (NL) | 2020-06-23 | — | — | US | disclosed |
| EP-3501533-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | Ferring B.V. (NL) | 2019-06-26 | — | — | EP | disclosed |
| US-10183029-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (NL) | 2019-01-22 | — | — | US | disclosed |
| US-20170348325-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING B.V. (NL) | 2017-12-07 | — | — | US | disclosed |
| WO-2016105190-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING B.V. (NL) | 2016-06-30 | — | — | WO | disclosed |
| EP-3037101-A1 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | Ferring B.V. (NL) | 2016-06-29 | — | — | EP | disclosed |
| US-20160175283-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | FERRING B.V. (NL) | 2016-06-23 | — | — | US | disclosed |
| WO-2016007421-A1 | METHODS AND COMPOSITIONS FOR MODULATING LUNG CANCER TUMOR INITIATING CELLS (TIC), AND OXYTOCIN RECEPTOR (OXTR) MODULATORY AGENTS FOR USE IN PRACTICING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20140235556-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. | 2014-08-21 | — | — | US | disclosed |
| EP-2760473-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | Biomed Valley Discoveries, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| CN-103930132-A | Compositions and methods of treating gliomas | BIOMED VALLEY DISCOVERIES INC | 2014-07-16 | — | — | CN | disclosed |
| WO-2013049045-A1 | COMPOSITIONS AND METHODS OF TREATING GLIOMAS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352962-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
| US-20160175283-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
| US-20170348325-A1 | OXYTOCIN RECEPTOR ANTAGONIST THERAPY IN THE LUTEAL PHASE FOR IMPLANTATION AND PREGNANCY IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGIES | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
| US-10183029-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
| US-10688106-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
| US-11752157-B2 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | OXTR, GNRHR, LHCGR | OXTR 1/4885AVPR2 8/4885AVPR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.